You are here: Industry Insights > Ocrevus

News List

Financial Report: Roche 1H Results contractpharma
July 23, 2021
Diagnostics Division sales grew 49% due to high demand for COVID-19 tests and strong momentum in routine testing.
New Data for Genentech’s Ocrevus (ocrelizumab) Reinforce Significant Benefit on Slowing Disease Progression in Relapsing and Primary Progressive Multiple Sclerosis americanpharmaceuticalreview
April 21, 2021
Genentech, a member of the Roche Group, announced new Ocrevus® (ocrelizumab) analyses supporting its significant benefit on disease progression in early-stage relapsing-remitting multiple sclerosis (RRMS) and primary progressive MS (PPMS) as well as ...
US FDA nod for Ocrevus (ocrelizumab) shorter 2-hour infusion for relapsing and primary progressive MS expresspharma
December 16, 2020
Approval based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the conventional Ocrevus dosing regimen.
FDA and EMA agree to review shorter infusion time of Roche’s Ocrevus pharmaceutical-technology
April 22, 2020
The US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have agreed to review Roche’s applications for a shorter infusion time of Ocrevus to treat relapsing or primary progressive multiple sclerosis (MS).
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis worldpharmanews
September 17, 2019
Roche announced longer-term data from the Phase III open-label extension studies of OPERA I, OPERA II and ORATORIO showed that patients who were treated with OCREVUS® (ocrelizumab) continuously for ...
Roche's Ocrevus continues winning streak as NICE flip-flops on initial rejection fiercepharma
May 12, 2019
Roche’s multiple sclerosis superstar Ocrevus has run into few obstacles on its path to nearly $1 billion in global sales this year.
Ocrevus finally available on NHS pharmatimes
May 09, 2019
After 21,000 people signed a charity petition, the first primary progressive multiple sclerosis (MS) drug has been made available on the NHS.
Thanks to Ocrevus, Roche outgrows biosimilars attack to best quarter of 2018 fiercepharma
February 01, 2019
A major concern at Roche lately has been whether it can keep its head above water in the face of biosimilar challenges.
Roche's Ocrevus shows earlier, better outcomes in primary progressive and relapsing MS pharmafile
November 20, 2018
Roche has unveiled new five-year data from three Phase 3 open-label extension studies investigating the efficacy of Ocrevus (ocrelizumab) in the treatment of relapsing
NICE ‘no’ for Roche’s Ocrevus pharmatimes
July 18, 2018
The National Institute for Health and Care Excellence has turned down NHS funding for Roche’s multiple sclerosis therapy Ocrevus.

Previous page 1 2 Next page